A PHASE I/II TRIAL OF CYCLOPHOSPHAMIDE, CARFILZOMIB, THALIDOMIDE AND DEXAMETHASONE (CYCLONE) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Mikhael, J. [1 ]
Reeder, C. [1 ]
Libby, E. [2 ]
Costa, L. [3 ]
Mayo, A. [1 ]
Bergsagel, L. [1 ]
Buadi, F. [4 ]
Pirooz, N. [1 ]
Lubben, J. [1 ]
Dueck, A. [1 ]
Stewart, A. [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Med Univ South Carolina, Charleston, SC 29425 USA
[4] Mayo Clin Rochester, Rochester, MN USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0295
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [1] Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma
    Mikhael, Joseph R.
    Reeder, Craig B.
    Libby, Edward N., III
    Costa, Luciano J.
    Bergsagel, P. Leif
    Buadi, Francis
    Mayo, Angela
    Gano, Katherine
    Wolf, Cassandra
    Dueck, Amylou Constance
    Stewart, A. Keith
    BLOOD, 2012, 120 (21)
  • [2] Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
    Mikhael, Joseph R.
    Reeder, Craig B.
    Libby, Edward N.
    Costa, Luciano J.
    Bergsagel, P. Leif
    Buadi, Francis
    Mayo, Angela
    Reddy, Sravan K. Nagi
    Gano, Katherine
    Dueck, Amylou C.
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (02) : 219 - 227
  • [3] A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
    Bringhen, Sara
    Cerrato, Chiara
    Petrucci, Maria Teresa
    Genuardi, Mariella
    Gentilini, Fabiana
    Conticello, Concetta
    Oliva, Stefania
    Pantani, Lucia
    Offidani, Massimo
    Palladino, Carmela
    Benevolo, Giulia
    Montefusco, Vittorio
    Astolfi, Monica
    Villani, Oreste
    Siniscalchi, Agostina
    Rocci, Alberto
    De Paoli, Lorenzo
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2013, 122 (21)
  • [4] Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study
    Palumbo, Antonio
    Rossi, Davide
    Bringhen, Sara
    Larocca, Alessandra
    Gentilini, Fabiana
    De Paoli, Lorenzo
    Omede, Paola
    Ballanti, Stelvio
    Cavallo, Federica
    Passera, Roberto
    Liberati, Anna Marina
    Boccadoro, Mario
    Gaidano, Gianluca
    Sonneveld, Pieter
    Corradini, Paolo
    BLOOD, 2014, 124 (21)
  • [5] Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Chung, Joo-Seop
    Joo, Young-Don
    Lee, Jae-Hoon
    Lee, Jung-Lim
    Ahn, Jae-Sook
    Moon, Joon-Ho
    Shin, Ho-Jin
    Choi, Young-Jin
    Lee, Won-Sik
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 62 - 67
  • [6] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
    Bringhen, Sara
    Petrucci, Maria Teresa
    Larocca, Alessandra
    Conticello, Concetta
    Rossi, Davide
    Magarotto, Valeria
    Musto, Pellegrino
    Boccadifuoco, Luana
    Offidani, Massimo
    Omede, Paola
    Gentilini, Fabiana
    Ciccone, Giovannino
    Benevolo, Giulia
    Genuardi, Mariella
    Montefusco, Vittorio
    Oliva, Stefania
    Caravita, Tommaso
    Tacchetti, Paola
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2014, 124 (01) : 63 - 69
  • [7] Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
    Leng, Siyang
    Bhutani, Divaya
    Raza, Shahzad
    Assal, Amer
    Pan, Samuel
    Hu, Jianhua
    Wei, Alexander
    Mapara, Markus
    Lentzsch, Suzanne
    BLOOD CANCER JOURNAL, 2020, 10 (02)
  • [8] Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
    Siyang Leng
    Divaya Bhutani
    Shahzad Raza
    Amer Assal
    Samuel Pan
    Jianhua Hu
    Alexander Wei
    Markus Mapara
    Suzanne Lentzsch
    Blood Cancer Journal, 10
  • [9] Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
    Palumbo, Antonio
    Bringhen, Sara
    Villani, Oreste
    Siniscalchi, Agostina
    Russo, Eleonora
    Uccello, Giuseppina
    Cerrato, Chiara
    Gilestro, Milena
    Rossi, Davide
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [10] Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
    Jakubowiak, Andrzej J.
    Dytfeld, Dominik
    Jagannath, Sundar
    Vesole, David H.
    Anderson, Tara B.
    Nordgren, Brian K.
    Lebovic, Daniel
    Stockerl-Goldstein, Keith E.
    Griffith, Kent A.
    Hill, Melissa A.
    Harvey, Colleen K.
    Dollard, Akari M.
    Ott, Robert
    Kelley, Susan L.
    Barrickman, Jennifer
    Kauffman, Michael
    Vij, Ravi
    BLOOD, 2010, 116 (21) : 376 - 377
12345